Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
Ligang XingYueyin PanYuan-Kai ShiYongqian ShuJifeng FengWei LiLejie CaoLifeng WangWei GuYong SongPuyuan XingYutao LiuWen GaoJiuwei CuiNana HuRutian LiHua BaoYang ShaoJinming YuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Osimertinib had potent activity against EGFR-T790M-positive NSCLC with CNS metastases. Dynamic monitoring of plasma EGFR may suffice for predicting clinical responses, mitigating the need for repeat CSF biopsy.See related commentary by Marmarelis and Bauml, p. 6077.